Rubicon Research Limited, founded in 1999 and listed on BSE and NSE in October 2025, is an R&D-driven specialty pharmaceutical formulations company focused on developing, manufacturing and commercialising complex generics, specialty products and drug-device combination therapies for regulated markets, primarily the United States. The company reported FY26 revenue of ₹1,753.96 Cr, growing 36.6% YoY, and sold approximately 5.05 billion extended units across its manufacturing network in FY26. Its portfolio spans oral solids, liquids, nasal, ophthalmic, injectable and topical formulations as well as drug-device combinations, with ~98% of revenue USD-denominated.[1][2][3]
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.
Sign in to see dividends, bonuses and splits - free.
Sign in